BIFLORA database (Hainan plant species)

	Status	2004-01-01 development existent
	Organisation	Bicoll Biotechnology (Shanghai) Co., Ltd.
	Group	Bicoll (Group)

Bicoll GmbH. (11/30/20). "Press Release: Bicoll Celebrates 20th Anniversary".

This year marks the 20th anniversary of Bicoll. On November 29th, 2000 we embarked on this exciting journey to deliver research services and natural compound libraries, and enable our partners to develop new effective drugs for patients. We would like to take a moment to celebrate, reflect, and summarize the achievements of the last two decades.

First and foremost, we are grateful to you, our loyal customers, partners, colleagues, and friends for your ongoing support and trust in Bicoll. Without you, we would not be here today.

For the past 20 years, we have developed our expertise in natural products and medicinal chemistry, while continuously learning, improving, and expanding the disease areas as well as fields of application we cover.

As of today, Bicoll has completed numerous pharmaceutical projects where we delivered bio-active small molecules in the fields of oncology, diabetes, inflammation, epilepsy, HIV, and other targets. Moreover, Bicoll had the opportunity to work with partner organizations on joint projects in crop protection, nutrition, and cosmetics. We strive to always improve, extend our fields of expertise, and expand research services to meet your evolving needs. The success we have achieved positions us robustly for the future and upholds our mission: to help bring a new generation of drugs to the market.

We look forward to continuing this journey with you for the next decades to come.

Yours sincerely,
Dr. Kai Lamottke
Managing Director

And the Bicoll Team in Shanghai, Munich, ‘s -Hertogenbosch & Houston

FIRST STEPS AND YEARS: BUILT ON NATURAL BIOLOGICAL DIVERSITY

2000 Drug development companies cannot satisfy the continuous growth in demand of new, high-quality active molecules addressing newly found drug targets. Bicoll solves this bottleneck by utilizing the selective forces of evolution in nature. The invention of an innovative, flexible and fast process allows to speed up modern drug discovery by selecting highly qualified small molecules as lead compounds.

2001-2003 Public-private-partnership special environmental protection project together with Deutsche Investitions- und Entwicklungsgesellschaft mbH (DEG). In 2003 – its third year of operation – Bicoll achieves its first after-tax profit.

2004 Bicoll is specialized in high-tech natural product chemistry with a focus to make compounds from natural resources compatible with drug discovery systems used in modern drug research. For that purpose, Bicoll’s primary products are optimized small molecule libraries for drug discovery in the biopharmaceutical industry. The starting material is generated from endemic Asian plant resources. The resulting libraries are then tested and developed for fee and milestone payments in co-operation. They are customized to the target protein of the partner’s indication field to ensure a high success rate in the initial screening and following development steps.

Knowledge against ignorance

Human negligence and recklessness regarding the environment as well as economic exploitation threatens biodiversity. Many of the precious plant resources of our planet have already come to the verge of extinction. In the fight against carelessness about the environment education is quintessential. For people to value the planet’s original habitat, they need to be educated about their surroundings. With this in mind, the BIFLORA database aims at the completion of a century old endeavour – the documentation of Hainan’s highly endangered plant species. The biodiversity has been partially documented in dried herbaria. These efforts will now be supplemented with precise geographic information, location, and photographs. Furthermore, unknown plants will be identified and documented during these activities.

INTERIM ACHIEVEMENTS:

YOUNGSTER YEARS IN THE PHARMACEUTICAL INDUSTRY

2006 Ricerca Biosciences, LLC and the Bicoll Group annouce a collaboration agreement. Ricerca and Bicoll combine their strengths in MedChem Services to offer innovative solutions that streamline drug discovery and development. With Ricerca’s network of business development representatives throughout the United States, a close interaction with clients can be ensured. Additionally, Ricerca leverages Bicoll’s medicinal chemistry and natural product chemistry technology for drug discovery for North American clients. One of the partners has been FoldRx. Bicoll’s achievements contribute to the $ 53 Mio. trade/sales of FoldRx to Pfizer.

2007 Genfit SA (ALGFT) (Lille, France) and Bicoll commit to joint drug discovery and development projects in the field of cardiovascular, inflammatory and metabolic diseases. As part of the joint research project “OLNORME: Occurrence of novel Ligands for a Nuclear Orphan Receptor in plant Metabolites”, active hits for a class of new drugs are identified, confirmed and their structures elucidated. A class of potent and bioavailable RAR-related orphan receptor alpha (RORa) agonists are identified in a plant extract library from Bicoll.[1]

2009 Bicoll and EMBL, the renowned international and inter-governmental research organisation, announce the successful completion of a joint research project which identified active compounds as new inhibitors of aurora kinases.

2011 Bicoll and Naturalpha SAS’s joint project focuses on the development of innovative and qualified botanical ingredients for food and nutraceutical applications. Goal is to prevent disorders that contain an inflammatory component. Chronic low grade inflammation that exists in both metabolic and neurodegenerative diseases is included in the scope of the program.[2]

2013 Bicoll initiates the EpimiRNA consortium, a project funded by the EU with €11.5 million to develop novel epilepsy therapeutics.[3]

NEW FIELDS, NEW WAYS: RELIABLE AND KNOWLEDGEABLE ALL THE TIME

2014 The research project EPICLEAP receives partial funding from the German Federal Ministry of Education and Research. Together with the Horst-Görtz-Endowment Institute for the Theory, History and Ethics of Chinese Life Sciences, Charité – Universitätsmedizin Berlin, the project scientifically evaluates more than 40.000 hand-written, pharmaceutical recipes from China, dating from the 18th to the 20th century.

2017 Bicoll becomes partner of the SimLeap Consortium (Symrise AG, Charité and Bicoll) to contribute to healthy food reformulation systems. Data-mining historical Asian recipes identifies plant derived compounds that function as a tool for sugar reduction.[4] (Patent PCT/EP2017/065457)

2018 Bicoll achieves promising anti-seizure results with a proprietary small molecule lead structure in different epilepsy models. The molecule was tested in human and rodent models in cooperation with University College London in the UK and the Royal College of Surgeons in Ireland.

2019 This year marks the start of precision medicine and individualized discovery of compounds through lab-on-a-chip technology using plant libraries and patient samples for the treatment of inflammation processes. Bicoll aims to have a prototype ready, to allow for individual predictions for the best treatment options for patients, and to identify the best compounds for the treatment.

2020 Bicoll’s total synthesis of Aureothin-derivatives helps Prof. Brack-Werner from the Institute of Virology at Helmholtz Zentrum München to identify a lead compound that combines strong anti-HIV activity, photostability and improved cell safety.[5]

FIELDS OF EXPERTISE & MORE

Bicoll’s plant-based small molecule libraries have a proven track record in the following fields as documented by published results and patents:

_______________________________________________________

Stay informed and register for the newsletter (at the bottom of this page) , LinkedIn (follow us) and Twitter (@BicollGroup).

Download PDF here.

[1] https://bicoll-group.com/wp-content/uploads/130829_Bicoll_Genfit_neoruscogenin_ENGLISH.pdf

[2] https://journals.sagepub.com/doi/pdf/10.1177/1934578X1501000416

[3] Prof. David C. Henshall, Prof. Hajo M. Hamer, MD, Prof. R. Jeroen Pasterkamp, PhD, Prof. David B. Goldstein, PhD, Prof. Jørgen Kjems, PhD, Prof. Jochen H. M. Prehn, PhD, Stephanie Schorge, PhD, Kai Lamottke, PhD, Felix Rosenow, MD, THE LANCET Neurology, Dec. 2016, DOI: http://dx.doi.org/10.1016/S1474-4422(16)30246.

[4] https://bicoll-group.com/wp-content/uploads/20200310_Bicoll_GmbH_SimLeap-ENG-final.pdf

[5] https://bicoll-group.com/wp-content/uploads/20200205_Bicoll_GmbH_Antiviral_HIV_ENG_final.pdf